Similar to This
Some Target, Sweetgreen, and Walmart managers are making six figures
Some Target, Sweetgreen, and Walmart managers are making six figures: While some tech firms are trimming managers, retail and hospitality companies ...
businessinsider.com/retail-store-managers-target-sweetgreen-pay-tech-middle-managers-2026-11
AI rewires finance as geopolitical risks intertwine
AI rewires finance as geopolitical risks intertwine: One transaction connects to various markets, and every link is an exposure, said GFTN’s Ravi Menon ...
sbr.com.sg/news/ai-rewires-finance-geopolitical-risks-intertwine
UAE’s Most Influential Finance Leaders 2026
UAE’s Most Influential Finance Leaders 2026: Khaleej Times recognises the UAE’s top 30 finance chiefs for steering resilience, backing investments and harnessing ...
khaleejtimes.com/leadership/top-leaders/uaes-most-influential-finance-leaders-2026
Africa: COP31's focus on delivery will fail Africa if climate finance and ...
Africa: COP31's focus on delivery will fail Africa if climate finance and technology continue to be designe...
allafrica.com/stories/202611090433.html
On Handelsblatt you can read news about companies, finance, politics, and technology. ➤ The No. 1 financial | & business newspaper. ➤ Substance counts. Show more
Novavax shares soar on license deal with Sanofi at lofty valuation
Novavax shares soar on license deal with Sanofi at lofty valuation: Novavax on Friday said it had struck a licensing deal worth at least $1 ...
reuters.com/business/healthcare-pharmaceuticals/frances-sanofi-covid-19-vaccine-deal-with-novavax-statement-2024-05-10/
Key FactsSanofi's Collaboration with Novavax for COVID-19 Vaccine
May 10, 2024 · Reading time: ~30 sec.
Summary created with AI assistance · Source: reuters.com
  • Sanofi has reached a licensing agreement with Novavax to sell a stand-alone COVID-19 vaccine and develop new flu-COVID-19 combination vaccines.

  • Novavax will receive an upfront payment of $500 million and could receive up to $700 million in development, regulatory and launch milestones, totaling up to $1.2 billion.

  • Sanofi will also take a minority equity stake below 5% in Novavax.

  • Novavax missed out on the COVID-19 vaccine windfall due to manufacturing issues that delayed its regulatory approval filing during the peak of the pandemic.